Website maintenance is scheduled for Saturday, October 12, and Sunday, October 13. Short disruptions may occur during these days.

brand logo

Am Fam Physician. 2023;107(6):657-658

This clinical content conforms to AAFP criteria for CME.

Author disclosure: No relevant financial relationships.

Case Scenario

An 82-year-old man presents to his family physician to discuss his kidney function test results. He has well-controlled hyperlipidemia and hypertension treated with 40 mg of atorvastatin and 20 mg of lisinopril daily. His body mass index is normal. He exercises three or four times per week for 30 minutes on a stationary bike and follows a Mediterranean diet. Recent laboratory testing found a blood urea nitrogen level of 29 mg per dL (10.35 mmol per L), serum creatinine level of 1.43 mg per dL (126.41 μmol per L), and an estimated glomerular filtration rate (eGFR) of 49 mL per minute per 1.73 m2 that was similar three months ago and not associated with albuminuria, classifying him with stage 3a chronic kidney disease (CKD). Before the visit, the patient shared the results with his brother-in-law, a retired cardiologist, who told him to request an urgent nephrology referral because the patient was in danger of progressing to kidney failure and eventually needing dialysis. The patient is concerned by this news and has many questions.

Clinical Commentary

CKD is abnormal kidney structure or function lasting more than three months.1 The condition affects more than 47 million people in the United States and is most often associated with long-standing hypertension and diabetes mellitus.2 CKD is associated with significant morbidity, mortality, and increased health care costs, particularly in patients requiring dialysis. It is an independent risk factor for cardiovascular disease and all-cause mortality.1 A 2016 report showed that Medicare spending for patients with CKD was more than $52 billion, representing 20% of all Medicare spending.2 It is unclear how much of that spending is related to the treatment of end-stage kidney disease compared with milder forms of CKD that may not progress to dialysis.

Already a member/subscriber?  Log In

Subscribe

From $165
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available
Subscribe

Issue Access

$59.95
  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

Lown Institute Right Care Alliance is a grassroots coalition of clinicians, patients, and community members organizing to make health care institutions accountable to communities and to put patients, not profits, at the heart of health care.

This series is coordinated by Kenny Lin, MD, MPH, deputy editor.

A collection of Lown Right Care published in AFP is available at https://www.aafp.org/afp/rightcare.

Continue Reading

More in AFP

More in PubMed

Copyright © 2023 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.